Q4 EPS Estimates for Kura Oncology Decreased by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Leerink Partnrs lowered their Q4 2025 EPS estimates for shares of Kura Oncology in a report issued on Thursday, November 13th. Leerink Partnrs analyst J. Chang now expects that the company will earn $0.18 per share for the quarter, down from their prior estimate of $0.19. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other research firms have also recently issued reports on KURA. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. UBS Group upped their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $25.11.

Kura Oncology Trading Up 4.9%

KURA stock opened at $11.20 on Monday. The firm has a market cap of $974.62 million, a P/E ratio of -4.52 and a beta of 0.34. The company’s 50-day simple moving average is $9.46 and its 200-day simple moving average is $7.49. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $16.68.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its position in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after buying an additional 3,072 shares during the period. State of Wyoming acquired a new stake in Kura Oncology in the 1st quarter worth approximately $48,000. PNC Financial Services Group Inc. raised its holdings in Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the period. Tower Research Capital LLC TRC boosted its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period. Finally, Pallas Capital Advisors LLC increased its position in Kura Oncology by 32.2% during the second quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after acquiring an additional 3,241 shares during the period.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 8,805 shares of the business’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares in the company, valued at $1,323,504.42. The trade was a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Kathleen Ford sold 6,902 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $11.18, for a total transaction of $77,164.36. Following the sale, the chief operating officer directly owned 105,373 shares of the company’s stock, valued at approximately $1,178,070.14. This represents a 6.15% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 122,675 shares of company stock worth $1,196,657. 6.40% of the stock is currently owned by insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.